AMRX•benzinga•
Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?
Summary
Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's unclear outlook.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 6, 2025 by benzinga